Research programme: beta-ketoacyl-acyl carrier protein synthase inhibitors - Merck & Co
Alternative Names: 3-Ketoacyl-acyl carrier protein synthase inhibitors - Merck & Co; FabF inhibitors- Merck & Co; FabH inhibitors - Merck & Co; Platencin; PlatensimycinLatest Information Update: 04 Nov 2017
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action FabF inhibitors; FabH inhibitors; Fatty acid synthetase complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (PO)
- 31 Mar 2011 Pharmacodynamics data from preclinical trials in Diabetes mellitus presented at the 241st American Chemical Society National Meeting (ACS-2011)